semaglutide free GLP-1 Forms & Info FDA Approves Oral Semaglutide for

4% with placebo, and vomiting (5%, 7% and 14%) vs

& Snyder, N

Researchers believe this may be due to how GLP-1 affects the gut by: Slowing motility Modulating nerve signaling Possibly reducing visceral hypersensitivity (pain response) There is also some early evidence that GLP-1 medications may reduce overall IBS symptom severity and medication use, although more long-term data is needed 6

Common examples include semaglutide (Ozempic and Wegovy) and liraglutide (Saxenda and Victoza)

An estimated 23.1% of those who took the highest dose of the drug experienced vomiting, while 36.4% experienced nausea and 27.4% experience diarrhea

(v) abdominal obesity can reduce chest compliance and functional residual capacity